Boluses of controlled release glass for supplementing ruminants with cobalt.

Boluses of controlled release glass containing cobalt and weighing approximately either 60 g or 14.5 g were administered to 22 steers and 21 sheep respectively. The steers were housed and slaughtered at intervals between 17 and 145 days after dosing. The boluses released more than 0.85 mg cobalt daily. In both untreated and dosed animals serum and liver vitamin B12 concentrations were at the upper end of the normal range. Two types of glass were administered to sheep. In five wethers one glass released 0.07 mg cobalt per day, and in 16 grazing lambs a second glass released more than 0.15 mg cobalt per day. Fourteen of the boluses were recovered from the lambs up to 276 days after dosing. The concentration of B12 in serum of lambs increased significantly from a mean +/- sd of 1.64 +/- 0.47 to 2.02 +/- 0.04 ng/ml serum and the concentration in liver from 3.84 +/- 0.85 to 4.99 +/- 0.72 micrograms/g dry weight liver.

Boluses of controlled release glass for supplementing ruminants with copper.

A controlled release glass was formulated into boluses weighing approximately 17 g or 75 g and administered to 19 lambs and 20 steers respectively. The animals were at pasture during the summer months. The lambs were slaughtered between 57 and 219 days after dosing when the mean concentration of copper in their livers had increased to 107.8 +/- 33.4 mg copper/kg fresh weight compared with 55.9 +/- 23.0 mg copper/kg fresh weight in undosed controls. The steers were slaughtered more than 140 days after dosing; the mean concentrations of copper in plasma had increased and the mean concentration of copper in liver was significantly greater than in undosed control steers (14.1 +/- 4.8 mg copper/kg fresh weight liver in dosed steers, 4.7 +/- 1.4 mg copper/kg in control steers) and was similar to the concentration in steers which had received 200 mg copper as copper calcium edetate (18.2 +/- 4.2 mg copper/kg fresh weight). In sheep the minimum rate of release of copper into the reticulorumen was 2.1 mg/day and in steers 11 mg/day.

Acute pancreatitis associated with the use of lisinopril.

OBJECTIVE: To report a case of acute pancreatitis associated with lisinopril use. CASE SUMMARY: A 67-year-old man with no past history of pancreatitis or its associated risk factors developed acute pancreatitis after taking lisinopril for two years. To date, the use of angiotensin-converting enzyme (ACE) inhibitors and development of pancreatitis has been described in the literature with captopril, enalapril maleate, and one case temporally related to lisinopril use. CONCLUSIONS: The use of ACE inhibitors as first-line agents in controlling hypertension and congestive heart failure has increased. In addition to monitoring for efficacy and commonly reported adverse effects, clinicians need to be aware that acute pancreatitis may occur with all ACE inhibitors.

The use of controlled-release glass for the controlled delivery of bioactive materials.

CRG can provide a useful supplement to other methods of controlled delivery. Some advantages of this approach are: The constituents of the CRG can be limited to biologically safe ionic species such as Na+, Ca2+ and PO4(3-). The release system is completely soluble in water and no residue remains. There is no evidence of any mechanism for biodegradation of the CRG and so one possible cause of premature or accelerated release is eliminated. The absolute release rate can be selected anywhere in a spectrum covering several orders of magnitude and the rate-controlling process has zero-order kinetics. The release rate can be selected to be pH-sensitive or pH-independent. Complex temporal release-rate patterns can be obtained readily by the choice of geometrical shape or composition profile of the device. The controlled release of organics or other heat-sensitive materials which cannot be incorporated in the glass can be realized by the use of composite structures in which the CRG is the rate-controlling constituent. A number of different functions can be performed by a single CRG-based device. For example, CRG can be used as a biomedical resorbable material in surgery and the CRG structural component can release an AM as it dissolves. Similarly the CRG of the sinter-composite used for organic AM release can itself release any selected inorganic adjuvant. CRG boluses containing either copper or cobalt and weighing approx. either 70 g or 15 g, have been administered to both cattle and sheep. More than 90% of the boluses remained either in the reticulum of trace element remained after dosing.(ABSTRACT TRUNCATED AT 250 WORDS)